Your Medication Isn't Working. Your Genes May Be Why.

Your CYP2D6 gene encodes an enzyme that sits in your liver and processes a quarter of all medications you might ever take. It’s the primary metabolizer of antidepressants like fluoxetine and venlafaxine, opioid painkillers like codeine and tramadol, beta-blockers, and antiarrhythmics. When CYP2D6 is working normally, it converts these drugs into inactive metabolites that your kidneys eliminate. Your body stays in balance.

But if you carry variants like *4, *10, or *17, or if you have fewer than the normal two copies of the gene, your enzyme works much slower. Roughly 7-10% of people with European ancestry are poor metabolizers of CYP2D6. For poor metabolizers, standard doses of antidepressants and opioids accumulate in the bloodstream to toxic levels. The drug doesn’t clear as expected. It keeps building up.

You might take an antidepressant and experience severe side effects within days: tremors, confusion, rapid heartbeat, or dangerous serotonin syndrome. You might think you’re allergic or that the drug is wrong for you. Your doctor might switch you to a different antidepressant, and the same thing happens. You’re not failing treatment. Your liver is processing the drug so slowly that it’s accumulating to dangerous levels. On the flip side, if you’re an ultra-rapid metabolizer with gene duplications, the drug is cleared so quickly that you never feel any benefit at all. You take it faithfully and nothing happens.

CYP2C19 is responsible for activating a pro-drug called clopidogrel, which you know as Plavix. After a heart stent or stroke, you’re prescribed clopidogrel to prevent clots. But clopidogrel is inert until your liver metabolizes it. CYP2C19 is the enzyme that does this activation. It also metabolizes many antidepressants, omeprazole (Prilosec), and similar heartburn medications.

If you carry *2 or *3 variants, you’re a poor metabolizer of CYP2C19. Roughly 2-15% of people have these variants depending on ancestry. If you’re a poor metabolizer taking clopidogrel, your liver cannot activate the drug into its active form, and you get zero antiplatelet benefit. You think you’re protected from clots after your stent. You’re not. Your risk of heart attack or stent thrombosis remains high because the medication isn’t working.

You might also be taking an antidepressant metabolized by CYP2C19 and not feeling any improvement, or experiencing side effects at a standard dose because the drug is accumulating. Ultra-rapid metabolizers (*17 variants) face the opposite problem: they activate drugs so quickly that standard doses produce no therapeutic benefit, and they may experience elevated bleeding risk with clopidogrel.

CYP2C9 metabolizes warfarin, the blood thinner prescribed to prevent clots in atrial fibrillation, after heart surgery, or with certain clotting disorders. It also processes NSAIDs like ibuprofen and naproxen, and several statin cholesterol drugs. For most people, standard warfarin doses achieve the right level of anticoagulation through trial and adjustment.

But if you have CYP2C9 *2 or *3 variants, you’re a poor metabolizer. Roughly 5-10% of people with European ancestry carry these variants. With poor CYP2C9 metabolism, standard warfarin doses do not clear from your bloodstream at the expected rate, and you accumulate excessive anticoagulation. The risk of serious bleeding spikes: bleeding in the brain, stomach, or into joints. Your INR (international normalized ratio, the measure of how thin your blood is) climbs too high too fast.

You might start warfarin at the standard dose and within a week be admitted to the hospital with bleeding complications. Your doctor might not realize this is a genetic metabolism problem. They might think you’re sensitive to warfarin and keep your dose lower than necessary, leaving you at risk of clots. Testing CYP2C9 before starting warfarin tells your doctor exactly what dose you need from day one.

VKORC1 encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K in your liver. Warfarin works by blocking this enzyme, preventing the recycling of vitamin K and reducing the clotting factors your blood needs. But VKORC1 variants affect how sensitive your system is to warfarin’s blocking effect.

If you carry the A allele of the VKORC1 -1639G>A variant, roughly 40% of people with European ancestry do, your enzyme is less efficient at recycling vitamin K. This means your blood clotting factors deplete faster when you take warfarin, and you achieve anticoagulation at much lower doses than the standard prescription. While CYP2C9 affects how quickly you clear the drug, VKORC1 affects how sensitive you are to the drug’s effect.

You might start warfarin at a typical dose and find that your INR shoots dangerously high within days. Your doctor adjusts downward. You stabilize at a dose much lower than most people need. This isn’t weakness or over-sensitivity. Your genes make you biologically require less warfarin to achieve the same anticoagulation. Conversely, if you have the G allele, you may need higher-than-average doses. Testing VKORC1 along with CYP2C9 gives your doctor a complete picture of your warfarin requirements.

SLCO1B1 encodes a hepatic statin transporter, a protein that actively pumps statin drugs from your bloodstream into your liver cells. Once inside liver cells, statins do their job of blocking cholesterol synthesis. The efficiency of this transport determines how much statin exposure your bloodstream experiences.

If you carry the *5 variant (rs4149056 C allele), roughly 15% of people do, this transporter works less efficiently. Statins don’t enter liver cells as effectively, so they remain in your bloodstream at higher concentrations, exposing your muscles and other tissues to statin drug levels they shouldn’t normally see. This is especially true for simvastatin, which depends heavily on SLCO1B1 transport.

You might start a statin for cholesterol and develop muscle pain (myalgia) or weakness (myopathy) at doses that don’t cause these problems in other people. You might blame the exercise or age. You might stop taking the statin because it doesn’t feel safe. Testing SLCO1B1 reveals whether muscle symptoms are genuinely drug-related and whether a dose reduction or switch to a different statin (like rosuvastatin or pravastatin, which don’t depend as heavily on this transporter) would solve the problem.

TPMT encodes thiopurine S-methyltransferase, an enzyme that metabolizes thiopurine drugs like azathioprine (Imuran) and 6-mercaptopurine (6-MP). These are immunosuppressants used to treat autoimmune conditions like lupus, inflammatory bowel disease, and rheumatoid arthritis. In people with normal TPMT activity, standard doses are metabolized efficiently and side effects are manageable.

But roughly 0.3% of people are poor metabolizers of TPMT, and another 10% are intermediate metabolizers. Poor metabolizers cannot break down thiopurine drugs efficiently, and toxic metabolites accumulate in blood and bone marrow cells, causing severe bone marrow suppression. This means your white blood cell count plummets, your red blood cells disappear, and your platelets vanish. You become vulnerable to infections, anemia, and bleeding.

You might start azathioprine at a standard dose to control your lupus or Crohn’s disease. Within weeks, your blood counts crash. You’re hospitalized for severe infection or bleeding. Your doctor stops the drug. You’re told you can’t tolerate it. But the real problem isn’t the drug; it’s that your genes cannot metabolize it at that dose. Testing TPMT before starting a thiopurine allows your doctor to dose appropriately or choose a different immunosuppressant altogether, preventing life-threatening bone marrow toxicity.